ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: TH-PO493

External Validation of the International IGA Nephropathy Prediction Tool Among a Filipino Cohort of Patients

Session Information

Category: Glomerular Diseases

  • 1303 Glomerular Diseases: Clinical‚ Outcomes‚ and Trials


  • Mala, Princess Jasmine Alongan, National Kidney and Transplant Institute, Quezon City, National Capital Region, Philippines

IgA nephropathy is the most common glomerulonephritis in the world. The incidence rate of primary GN varies between 0.2/100,000/year and 2.5/100,000/year. It is the most common glomerulonephritis (34.4%) in the Philippines. Recently, a new International IgAN prediction tool was published and was walidated in large multi-ehnic cohort, hence, this study aimed to validate this tool among Filipino cohort.


This was a retrospective, cohort study among Filipino IgA nephropathy patients determining their score utilizing the International IgAN prediction tool. This was conducted at National Kidney and Transplant Institute from January 2015- 2017. The list of all patients who fulfilled the inclusion criteria was retrieved.


A total of 151 participants were included in the study, with a mean age of 33 years and predominantly females (61.59%). The mean creatinine was 1.5 mg/dL and an eGFR of 56 mL/min/1.73m2. Using the International IgAN prediction tool, the predicted eGFR decline was highest at 46% among the highest risk group. Model discrimination result showed C statistics = 0.66. Result using the International IgAN prediction tool overestimated the observed risk of primary outcome at 3 years post biopsy. Result showed both the observed and the predicted eGFR showed a higher decline among the highest IgAN risk group.


Utilizing the International IgAN prediction tool among Filipino cohort able to predict the decline in eGFR even as early as 36 months from the time of biopsy. This tool can be used among Filipinos in predicting decline in eGFR.